Literature DB >> 20621654

Anti-Ku antibodies: Clinical, genetic and diagnostic insights.

C Belizna1, D Henrion, A Beucher, C Lavigne, A Ghaali, H Lévesque.   

Abstract

Anti-Ku antibodies are reported in various connective tissue diseases and the Ku complex can be responsible for a very strong autoimmune answer in autoimmune disease. Nowadays, anti-Ku antibodies are detected by ELISA, counterimmunoelectrophoresis (CIE), immunoblot (IB) and new highly performant techniques. Although the prevalence of anti-Ku antibodies is not homogenous, depending on several features such as disease type, genetic and geographical clustering, and also method of detection, they could be found in 55% overlap PM/systemic sclerosis patients. Moreover, anti-Ku antibodies are not associated with a particular clinical outcome, and especially with cancer related to myositis. 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20621654     DOI: 10.1016/j.autrev.2010.05.020

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  12 in total

Review 1.  Serologic laboratory findings in malignancy.

Authors:  Félix Fernández Madrid; Marie-Claire Maroun
Journal:  Rheum Dis Clin North Am       Date:  2011-11       Impact factor: 2.670

Review 2.  The Ku complex: recent advances and emerging roles outside of non-homologous end-joining.

Authors:  Sanna Abbasi; Gursimran Parmar; Rachel D Kelly; Nileeka Balasuriya; Caroline Schild-Poulter
Journal:  Cell Mol Life Sci       Date:  2021-04-15       Impact factor: 9.261

3.  Camptocormia as a clinical manifestation of polymyositis/systemic sclerosis overlap myositis associated with anti-Ku.

Authors:  Thierry Zenone; Nathalie Streichenberger; Marie Puget
Journal:  Rheumatol Int       Date:  2012-03-28       Impact factor: 2.631

Review 4.  Primary biliary cirrhosis and the nuclear pore complex.

Authors:  Carolina Duarte-Rey; Dimitrios Bogdanos; Chen-Yen Yang; Krista Roberts; Patrick S C Leung; Juan-Manuel Anaya; Howard J Worman; M Eric Gershwin
Journal:  Autoimmun Rev       Date:  2012-04-01       Impact factor: 9.754

Review 5.  The manifestation of myositis in tick-borne encephalitis as a prophet of severe disease course: a rare case report.

Authors:  Marija Montvydaite; Goda Seskute; Gabriele Minseviciute; Linas Svetikas; Dalia Miltiniene; Sandra Selickaja; Irena Butrimiene
Journal:  Clin Rheumatol       Date:  2022-01-13       Impact factor: 2.980

6.  The prevalence and clinical significance of anti-PUF60 antibodies in patients with idiopathic inflammatory myopathy.

Authors:  Ya-Mei Zhang; Han-Bo Yang; Jing-Li Shi; He Chen; Xiao-Ming Shu; Xin Lu; Guo-Chun Wang; Qing-Lin Peng
Journal:  Clin Rheumatol       Date:  2018-03-15       Impact factor: 2.980

7.  Single-specificity anti-Ku antibodies in an international cohort of 2140 systemic sclerosis subjects: clinical associations.

Authors:  S Hoa; M Hudson; Y Troyanov; S Proudman; J Walker; W Stevens; M Nikpour; S Assassi; M D Mayes; M Wang; M Baron; M J Fritzler
Journal:  Medicine (Baltimore)       Date:  2016-08       Impact factor: 1.889

8.  In Vivo Chronic Stimulation Unveils Autoreactive Potential of Wiskott-Aldrich Syndrome Protein-Deficient B Cells.

Authors:  Maria Carmina Castiello; Francesca Pala; Lucia Sereni; Elena Draghici; Donato Inverso; Aisha V Sauer; Francesca Schena; Elena Fontana; Enrico Radaelli; Paolo Uva; Karla E Cervantes-Luevano; Federica Benvenuti; Pietro L Poliani; Matteo Iannacone; Elisabetta Traggiai; Anna Villa; Marita Bosticardo
Journal:  Front Immunol       Date:  2017-05-02       Impact factor: 7.561

Review 9.  Bench to bedside review of myositis autoantibodies.

Authors:  Boaz Palterer; Gianfranco Vitiello; Alessia Carraresi; Maria Grazia Giudizi; Daniele Cammelli; Paola Parronchi
Journal:  Clin Mol Allergy       Date:  2018-03-07

Review 10.  Integrating the DNA damage and protein stress responses during cancer development and treatment.

Authors:  Vassilis G Gorgoulis; Dafni-Eleftheria Pefani; Ioannis S Pateras; Ioannis P Trougakos
Journal:  J Pathol       Date:  2018-07-19       Impact factor: 7.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.